Claims
- 1. A method of treating a non-viral and non-tumor, TH2 cell mediated disease comprising administering an immune response modifier compound selected from the group consisting of imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines in an amount effective to inhibit TH2 cell mediated immune response, with the proviso that said disease is other than eczema.
- 2. The method of claim 1, wherein said disease is a parasitic infection.
- 3. The method of claim 1, wherein said disease is a bacterial infection.
- 4. The method of claim 1, wherein said disease is a fungal infection.
- 5. The method of claim 1, wherein said disease is selected from the group consisting of asthma, allergy, leprosy, systemic lupus erythematosis, Ommen's syndrome, leishmaniasis, toxoplasma infection, trypanosome infection, candidiasis, and histoplasmosis.
- 6. The method of claim 1, wherein said disease is selected from the group consisting of asthma and allergic rhinitis.
- 7. The method of claim 1, wherein said compound is administered via oral or nasal inhalation.
- 8. The method of claim 1, wherein said compound is administered via a topical cream or gel.
- 9. The method of claim 1, wherein said compound is selected from the group consisting of 4-amino-2-ethoxymethyl-.alpha.,.alpha.-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol and 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine.
- 10. The method of claim 1, wherein said immune response modifier compound is a compound of Formula IX ##STR10## or a pharmaceutically acceptable salt thereof, wherein
- R.sub.19 is selected from the group consisting of alkyl containing one to six carbon atoms and hydroxyalkyl containing one to six carbon atoms; and
- R.sub.29 is selected from the group consisting of hydrogen, alkyl containing one to six carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to four carbon atoms and the alkyl moiety contains one to four carbon atoms, and hydroxyalkyl containing one to four carbon atoms.
- 11. The method according to claim 10, wherein said R.sub.19 is 2-methylpropyl or 2-hydroxy-2-methylpropyl.
- 12. A method according to claim 10, wherein said R.sub.29 is selected from the group consisting of hydrogen, methyl, butyl, hydroxymethyl, ethoxymethyl, and methoxymethyl.
Parent Case Info
This application is a continuation-in-part of prior filed co-pending provisional application Ser. Nos. 60/029,301, filed Oct. 25, 1996, and 60/045,331, filed May 1, 1997, and claims the benefit of the filing dates thereof under 35 U.S.C. .sctn. 119(e).
US Referenced Citations (13)
Foreign Referenced Citations (4)
Number |
Date |
Country |
385630 |
Sep 1990 |
EPX |
394026 |
Oct 1990 |
EPX |
9320847 |
Oct 1993 |
WOX |
9726883 |
Jul 1997 |
WOX |
Non-Patent Literature Citations (2)
Entry |
Hammerbeck, et al, The Imidazoquinolines and Related Compounds as Inhibitors of Pulmonary Eosinophilia. American Journal of Respiratory and Critical Care Medicine, Apr. 1997, vol. 155, No. 4, part 2. |
Varner et al: "Effects of Imiquimod on Post-Viral Asthma-Like Syndrome", J of Allergy and Clinical Immunology, vol. 99, No. 1(2), Jan. 1997, p. s127, XP002055521, Abstract 516. |